Valeant-Allergan duel continues
Valeant may crank up the pressure on Allergan: Bloomberg reports that the Canadian drugmaker indicated during its third-quarter earnings call that it may increase its bid. Allergan has argued that Valeant has offered too little for the company, but its points of resistance also include allegations that Valeant would not provide the financial support Allergan's products need.
The battle over the Botox-and-more portfolio has been raging for months and has grown to include allegations of misconduct and misrepresentation.
Allergan shareholders will vote for or against the takeover on December 18.